Early treatment volume reduction rate as a prognostic factor in patients treated with chemoradiotherapy for limited stage small cell lung cancer
Radiation Oncology Journal. 2015;33(2):117 
Treatment patterns and outcomes for limited stage small cell lung cancer treated with chemoradiotherapy
Lung Cancer. 2019;127:S85
44P INVESTIGATING GENDER AS PROGNOSTIC FACTOR IN PATIENTS WITH LIMITED DISEASE SCLC TREATED WITH CHEMORADIOTHERAPY
Lung Cancer. 2013;80:S19-S20
Chemoradiotherapy with or without granulocyte-macrophage colony-stimulating factor in the treatment of limited-stage small-cell lung cancer: A prospective phase III randomized study of the Southwest Oncology Group
Lung Cancer. 1995;13(3):349
P-56 Early concurrent normo- and hyperfractionated chemoradiotherapy in limited small cell lung cancer (LSCLC). Experience with 34 treated patients
Lung Cancer. 2003;41:S105
Treatment Response as Prognostic Factor in Patients Treated With Chemoradiation Therapy for Limited-Stage Small Cell Lung Cancer
International Journal of Radiation Oncology*Biology*Physics. 2015;93(3):E415-E416
Pre-treatment prognostic factors in patients with Stage III non-small cell lung cancer treated with hyperfractionated radiation therapy with or without concurrent chemotherapy
Lung Cancer. 1995;13(3):354-355
80PD PROGNOSTIC IMPORTANCE OF GROSS TUMOR VOLUME DEFINED BY UTILIZING 18-FDG-PET/CT IN STAGE IIIB NON-SMALL CELL LUNG CARCINOMA TREATED WITH DEFINITIVE CHEMORADIOTHERAPY
Lung Cancer. 2011;71:S40-S41
Treatment of Limited-Stage Small Cell Lung Cancer
Lung Cancer. 2003;186-206
Pre-treatment prognostic factors in patients with Stage III non-small cell lung cancer treated with hyperfractionated radiation therapy with or without concurrent chemotherapy
Lung Cancer. 1995;13(1):21-30